Cydan Accelerator Using $16M to Boost Orphan Drug Players
By Randy Osborne
Thursday, April 11, 2013
Backed by $16 million from investors that include Pfizer Inc.'s venture arm, a new orphan drug accelerator called Cydan LLC aims to spin out as many as five new companies in the first four years.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.